title: Routine cerebrospinal fluid enterovirus polymerase chain reaction testing reduces hospitalization and antibiotic use for infants 90 days of age or younger.
abstract: OBJECTIVE
  The goal was to evaluate the impact of cerebrospinal fluid enterovirus polymerase chain reaction testing on the length of hospitalization and the duration of antibiotic use for infants < or = 90 days of age with suspected aseptic meningitis.
  
  
  METHODS
  This retrospective cohort study was conducted at an urban, tertiary-care children's hospital. Data were collected for 478 patients < or = 90 days of age for whom cerebrospinal fluid enterovirus polymerase chain reaction testing was performed during the enteroviral seasons of 2000 to 2006. The length of hospitalization and the duration of antibiotic use were assessed.
  
  
  RESULTS
  Cerebrospinal fluid enterovirus polymerase chain reaction test results were positive for 154 patients (34.8%). The mean length of stay was 3.65 days. The median polymerase chain reaction turnaround time was 23 hours. In multivariate analysis, having a positive cerebrospinal fluid enterovirus polymerase chain reaction result was associated with a 1.54-day decrease in the length of stay and a 33.7% shorter duration of antibiotic use. When patients were stratified according to the presence or absence of pleocytosis, both groups demonstrated significant reductions in the length of stay with positive cerebrospinal fluid enterovirus polymerase chain reaction results (1.32 and 1.38 days, respectively). Furthermore, increasing the polymerase chain reaction turnaround time by 24 hours increased the length of stay by 13.6% for patients with positive cerebrospinal fluid enterovirus polymerase chain reaction results.
  
  
  CONCLUSIONS
  Having positive cerebrospinal fluid enterovirus polymerase chain reaction results decreases the length of hospitalization and the duration of antibiotic use for young infants. These results support the routine use of this test during periods of peak enterovirus prevalence.
authors.affiliation: Division of Infectious Diseases, Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104, USA.
authors.forename: Rebecca L
authors.initials: RL
authors.lastname: King
authors.forename: Scott A
authors.initials: SA
authors.lastname: Lorch
authors.forename: Daniela M
authors.initials: DM
authors.lastname: Cohen
authors.forename: Richard L
authors.initials: RL
authors.lastname: Hodinka
authors.forename: Keri A
authors.initials: KA
authors.lastname: Cohn
authors.forename: Samir S
authors.initials: SS
authors.lastname: Shah
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D015331:Cohort Studies; D004770:Enterovirus / Q000235:genetics* / Q000302:isolation & purification; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007902:Length of Stay / Q000706:statistics & numerical data*; D007958:Leukocyte Count; D007964:Leukocytosis / Q000134:cerebrospinal fluid / Q000188:drug therapy; D008297:Male; D008582:Meningitis, Aseptic / Q000188:drug therapy / Q000821:virology*; D015999:Multivariate Analysis; D012367:RNA, Viral / Q000134:cerebrospinal fluid*; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D012367:RNA, Viral